TAK · Healthcare · $56.8B
$17.86-1.81%
What's this stock's score right now?
See its score for free — revenue and money flow, graded on one standard.
Quarterly Financials
6/'26
Preliminary · some items pending
3/'26 vs prev quarter
Quarterly Revenue Growth
“타케다의 핵심 성장 동력은 앞으로 12개월 안에 출시 예정인 신약 3종이에요.”
In the company's words · 2026 4분기 earnings call